Why did Meta offer $100M to AI researchers?
How are U.S. tariffs affecting Nike’s costs?
What impact will AI have on Salesforce jobs?
Why did Trump drop 'Made in USA' phone label?
How does the U.S.-China trade deal affect markets?
Why are investors flocking to AI-related stocks?
How did recovery of Air India black boxes impact investigation?
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
benzinga.com/news/health-care/25/06/46095010/gilead-bets-on-kymeras-cdk2-molecular-glue-degrader-for-new-cancer-therapies
Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2…
This story appeared on benzinga.com, 2025-06-25 13:23:04.